AU2001242965A1 - Method of inhibiting the expression of inflammatory cytokines and chemokines - Google Patents

Method of inhibiting the expression of inflammatory cytokines and chemokines

Info

Publication number
AU2001242965A1
AU2001242965A1 AU2001242965A AU4296501A AU2001242965A1 AU 2001242965 A1 AU2001242965 A1 AU 2001242965A1 AU 2001242965 A AU2001242965 A AU 2001242965A AU 4296501 A AU4296501 A AU 4296501A AU 2001242965 A1 AU2001242965 A1 AU 2001242965A1
Authority
AU
Australia
Prior art keywords
chemokines
expression
inflammatory cytokines
man
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001242965A
Inventor
Tove Andersson
Sven Pettersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astareal AB
Original Assignee
Astacarotene AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene AB filed Critical Astacarotene AB
Publication of AU2001242965A1 publication Critical patent/AU2001242965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of inhibiting the expression of inflammatory cytokines and chemokines in an animal or man, is disclosed. The method comprises administration to said animal or man of at least one type of xanthophyll, e.g. astaxanthin, in an amount inhibiting the expression of inflammatory cytokines and chemokines in said animal or man. Use of at least one type of xanthophyll, such as astaxanthin, for the preparation of a medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines in an animal or man, is described. Further, a commercial package containing a medicament comprising at least one type of xanthophyll, e.g. astaxanthin, and written and/or data carrier instructions for administation to an animal or man of the medicament for the prophylactic and/or therapeutic inhibition of the expression of inflammatory cytokines and chemokines, is disclosed.
AU2001242965A 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines Abandoned AU2001242965A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0001071 2000-03-27
SE0001071A SE0001071D0 (en) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines
PCT/SE2001/000600 WO2001072296A1 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines

Publications (1)

Publication Number Publication Date
AU2001242965A1 true AU2001242965A1 (en) 2001-10-08

Family

ID=20279020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001242965A Abandoned AU2001242965A1 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines

Country Status (8)

Country Link
EP (1) EP1267857B1 (en)
JP (1) JP2003528139A (en)
AT (1) ATE353639T1 (en)
AU (1) AU2001242965A1 (en)
CA (1) CA2405479C (en)
DE (1) DE60126591D1 (en)
SE (1) SE0001071D0 (en)
WO (1) WO2001072296A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002349784A1 (en) * 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
JPWO2005074907A1 (en) 2004-02-04 2007-09-13 富士化学工業株式会社 Gene expression regulator
JP2006008714A (en) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd Matrix metalloproteinase inhibitor
JP2006008718A (en) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd Cyclooxygenase activity inhibitor
JP2006008719A (en) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd Blood peroxidized-lipid inhibitor
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155736A (en) * 1991-12-10 1993-06-22 Nakano Seiyaku Kk Cosmetic
JPH0799924A (en) * 1993-09-30 1995-04-18 Nippon Suisan Kaisha Ltd Stabilized powder of phaffia coloring matter oil containing astaxanthin as main component and its production
JPH07300421A (en) * 1994-04-28 1995-11-14 Itano Reitou Kk Anti-inflammatory agent
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US5886053A (en) * 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (en) * 1995-10-26 1997-05-13 Suntory Ltd Antistress composition
JPH09143063A (en) * 1995-11-22 1997-06-03 Kose Corp Composition suitable for external use
SE522246C2 (en) * 1997-02-27 2004-01-27 Astacarotene Ab Oral preparation for prophylactic and therapeutic treatment of Helicobacter Sp. infection
AU752468B2 (en) * 1997-04-04 2002-09-19 Phyllis E. Bowen Lutein esters having high bioavailability
SE512531C2 (en) * 1997-09-04 2000-03-27 Astacarotene Ab Use of at least one type of xanthophyll for the manufacture of a medicament for the prophylactic and / or therapeutic improvement of mammalian muscle function and / or treatment of mammalian muscle disorders or disorders

Also Published As

Publication number Publication date
JP2003528139A (en) 2003-09-24
WO2001072296A1 (en) 2001-10-04
EP1267857A1 (en) 2003-01-02
CA2405479A1 (en) 2001-10-04
EP1267857B1 (en) 2007-02-14
DE60126591D1 (en) 2007-03-29
SE0001071D0 (en) 2000-03-27
ATE353639T1 (en) 2007-03-15
CA2405479C (en) 2010-11-16

Similar Documents

Publication Publication Date Title
YU57600A (en) Bicyclic hydroxamic acid derivatives
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
WO2001072728A3 (en) Novel piperazine derivatives
EP1137403A4 (en) Sustained release tablet containing hydrocolloid and cellulose ether
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU3850600A (en) Dalda analogs and their use
AU2084801A (en) Antiviral medication
SE9802208D0 (en) Novel compounds
MX9800408A (en) Cyclo-oxygenase inhibitor and amidine derivative salts, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing said salts.
AU1185801A (en) Novel compounds
CA2085258A1 (en) Method for growth promotion of animals and powder compositions containing killed microbial cells of bacteria belonging to genus clostridium
AU2001242965A1 (en) Method of inhibiting the expression of inflammatory cytokines and chemokines
ES2174113T3 (en) NEW DERIVATIVES OF ((3-ALCOXI-FENOXI) -ETIL) -DIALQUILAMINE AND ITS USE AS LOCAL ANESTHETICS.
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
GEP20043231B (en) Resorcinol Composition
WO2001024803A3 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
AU7470098A (en) Antithrombotic agents
JP2003528139A5 (en)
AU3903701A (en) Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase
WO2002067851A3 (en) Method for treating fibrotic diseases or other indications iiic
DK171883A (en) Method for distribution of goods, and sales module for distributing goods
WO2001007029A3 (en) Substituted guanidines and the use thereof
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
AUPM493194A0 (en) Therapeutic agent for inhibiting the conversion of epithelial cells to tumours
AU2001274000A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them